The first step to control eradicate BVD is to eliminate persistently infected (PI) animals and determine the prevalence of antibodies against the viral causal agent in order to monitor the virus circulation. The first generations of diagnostic ELISA kits utilized the extracts of virus infected cell cultures as ELISA detector antigens (
14,
15). Several ELISAs have been recently developed to detect
BVDV infections using recombinant NS3 protein (
16-
19). Eukaryotic or prokaryotic recombinant NS3 is used for this purpose and this protein has shown high sensitivity and specificity to detect
BVDV infection in comparison with whole virus antigen (
16,
20). Thus, production of a recombinant form of NS3 in large amounts is economically very important and can be very useful to manufacture
BVDV antibody ELISA kits. Although it is shown that eukaryotic expression of NS3 increases sensitivity and specificity of ELISA kits (
18), prokaryotic expression of NS3 is still considered, since it is simple and less expensive than eukaryotic expression of the protein.
So far, several ELISAs are developed using prokaryotically expressed NS3 to detect anti-
BVDV antibodies. Reddy et al. (
17) cloned a 917-bp segment of NS3 (p80) into pGex-2T plasmid vector containing the glutathione-S-transferase (GST) gene and the recombinant protein was expressed in
E. coli and used as an ELISA antigen to detect anti-
BVDV antibodies. A 1152-bp cDNA fragment of NS3 (2/3rd of NS3 gene from C-terminal) was cloned into pGEMT Easy Vector and expressed in
E. coli by Bhatia et al. (
21) and used as a detector ELISA antigen in their developed competitive inhibition ELISA (CI-ELISA) using a monoclonal antibody. Lecomte et al. (
16) used a recombinant 80 kDa antigen of the
BVDV/Osloss virus strain as a fusion protein with β-galactosidase to detect
BVDV specific antibodies by ELISA. They also developed a competitive ELISA which was more specific than the direct assay.
Vanderheijden et al. (
18) inserted a 2183-nucleotide fragment containing encoding sequence of p80 (Osloss strain) into the pARHS3 plasmid and analyzed the expressed protein by a competitive ELISA. Although the prokaryotic expression of recombinant NS3 is a simple and inexpensive method, compared to the eukaryotic expression, researchers tried to develop competitive ELISAs by monoclonal antibodies and/or eukaryotically expressed recombinant NS3 molecule to increase sensitivity and specificity of the assay. In fact, one of the major problems of prokaryotic expression of NS3 molecule, particularly whole NS3 molecule, is that it is a large insoluble protein which aggregates as inclusion bodies in the bacterial host cells. Thus, researchers had to use high concentration of urea to solubilize the recombinant NS3 protein (inclusion bodies) and then renature it by gradient dialysis of the solution and it is obviously a time-consuming and expensive process. This problem was solved by another plasmid vector, pMAL-c2X, to clone and express the recombinant NS3 molecule used in this study. This vector encodes a maltose binding protein at the N-terminal part of the molecule which is a soluble protein and can even solubilize the recombinant protein expressed with it as a fusion protein (
22,
23).
MBP tag makes it possible to purify the recombinant protein by amylose-resin. In addition, with the enhanced solubility of the expressed recombinant NS3, there was no need to treat the recombinant protein with urea for the purification. The current study developed an indirect ELISA using the recombinant MBP-NS3 molecule as an ELISA detector antigen. The protein was expressed in E. coli in a simple and inexpensive manner and it was sufficiently soluble to be purified without any treatment. MBP-NS3 based ELISA showed a high degree of sensitivity and specificity in comparison with the results of VNT; kappa coefficients indicated a very high correlation between MBP-NS3-ELISA with VNT (kappa = 0.935, P < 0.001) and the commercial ELISA kit (kappa = 0.802, P < 0.001), although there were some differences.
Nine out of 150 positive samples by VNT were negative by MBP-NS3-ELISA. This could be due to 1) a recent infection which results in the production of IgM; therefore, the OD values of such serum samples may decrease significantly causing the samples to be determined as negative by MBP-NS3-ELISA, 2) presence of non-specific inhibitor factors in the tested serum samples that prevented virus propagation in the cell culture, and 3) vaccination of animals with an inactive vaccine that induces the production of neutralizing antibodies but not antibodies against BVDV NS3 protein. On the other hand, 3 VNT negative samples were positive by MBP-NS3-ELISA. This could also be due to the strain of the employed virus in VNT and/or the amount (TCID50) of the employed virus in VNT. In this study, maximum recommended TCID50 of the virus (400 TCID50) was utilized in VNT. So, it was more stringent and this could decrease the sensitivity and increase the specificity of the assay. The differences between the results of MBP-NS3-ELISA and the commercial ELISA kit probably resulted from the type of employed ELISA detector antigen(s) or standardization of the procedures.
Meanwhile, the developed ELISA is a simple ELISA which has no need to monoclonal antibodies to increase sensitivity or specificity of the assay. Statistical analyses showed that this developed ELISA is highly sensitive and specific in comparison with the viral neutralization test, which is the reference test for the serological diagnosis of BVDV. Developing such a simple, sensitive, and specific ELISA which is much less expensive than the available commercial ELISA kits can improve the detection of BVDV infections, help to eliminate the disease from herds, and decrease the economic losses caused by this disease. The current study developed a new simple indirect ELISA with a prokaryotically expressed recombinant whole NS3 molecule as ELISA antigen to detect anti-BVDV antibodies in sera of the infected cattle. The developed ELISA showed high sensitivity and specificity with respect to VNT.